Shuttle Pharmaceuticals Net Income
| SHPH Stock | USD 1.11 0.08 7.77% |
As of the 15th of February 2026, Shuttle Pharmaceuticals has the Coefficient Of Variation of (1,480), risk adjusted performance of (0.05), and Variance of 98.3. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Shuttle Pharmaceuticals, as well as the relationship between them.
Shuttle Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Shuttle Pharmaceuticals' valuation are provided below:We have found one hundred twenty available fundamental trend indicators for Shuttle Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. Traders should compare all of Shuttle Pharmaceuticals current fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -2.8 M | -2.7 M | |
| Net Loss | -8.2 M | -7.8 M | |
| Net Loss | -8.2 M | -7.8 M | |
| Net Loss | (1.02) | (0.97) |
Shuttle | Net Income | Build AI portfolio with Shuttle Stock |
The Net Income trend for Shuttle Pharmaceuticals offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Shuttle Pharmaceuticals is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Shuttle Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Shuttle Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Shuttle Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Shuttle Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Shuttle Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Shuttle Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (9.14 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Shuttle Net Income Regression Statistics
| Arithmetic Mean | (2,463,600) | |
| Coefficient Of Variation | (136.57) | |
| Mean Deviation | 2,878,201 | |
| Median | (626,139) | |
| Standard Deviation | 3,364,596 | |
| Sample Variance | 11.3T | |
| Range | 8.9M | |
| R-Value | (0.83) | |
| Mean Square Error | 3.7T | |
| R-Squared | 0.69 | |
| Significance | 0.000035 | |
| Slope | (554,322) | |
| Total Sum of Squares | 181.1T |
Shuttle Net Income History
Other Fundumenentals of Shuttle Pharmaceuticals
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Shuttle Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Shuttle Pharmaceuticals is extremely important. It helps to project a fair market value of Shuttle Stock properly, considering its historical fundamentals such as Net Income. Since Shuttle Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Shuttle Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Shuttle Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Shuttle introduce new products? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Shuttle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Shuttle Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Shuttle Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Shuttle Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Shuttle Pharmaceuticals.
| 11/17/2025 |
| 02/15/2026 |
If you would invest 0.00 in Shuttle Pharmaceuticals on November 17, 2025 and sell it all today you would earn a total of 0.00 from holding Shuttle Pharmaceuticals or generate 0.0% return on investment in Shuttle Pharmaceuticals over 90 days. Shuttle Pharmaceuticals is related to or competes with Akanda Corp, Heart Test, Universe Pharmaceuticals, Theriva Biologics, Biovie, ISpecimen, and Redhill Biopharma. Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery,... More
Shuttle Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Shuttle Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Shuttle Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.07) | |||
| Maximum Drawdown | 55.61 | |||
| Value At Risk | (17.24) | |||
| Potential Upside | 15.69 |
Shuttle Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Shuttle Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Shuttle Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Shuttle Pharmaceuticals historical prices to predict the future Shuttle Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.61) | |||
| Total Risk Alpha | (1.42) | |||
| Treynor Ratio | 0.5506 |
Shuttle Pharmaceuticals February 15, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | 0.5606 | |||
| Mean Deviation | 7.44 | |||
| Coefficient Of Variation | (1,480) | |||
| Standard Deviation | 9.91 | |||
| Variance | 98.3 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.61) | |||
| Total Risk Alpha | (1.42) | |||
| Treynor Ratio | 0.5506 | |||
| Maximum Drawdown | 55.61 | |||
| Value At Risk | (17.24) | |||
| Potential Upside | 15.69 | |||
| Skewness | 0.1307 | |||
| Kurtosis | 1.24 |
Shuttle Pharmaceuticals Backtested Returns
Shuttle Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0391, which indicates the firm had a -0.0391 % return per unit of risk over the last 3 months. Shuttle Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Shuttle Pharmaceuticals' Risk Adjusted Performance of (0.05), coefficient of variation of (1,480), and Variance of 98.3 to confirm the risk estimate we provide. The entity has a beta of -1.24, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Shuttle Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Shuttle Pharmaceuticals is expected to outperform it. At this point, Shuttle Pharmaceuticals has a negative expected return of -0.39%. Please make sure to validate Shuttle Pharmaceuticals' value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Shuttle Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.12 |
Insignificant predictability
Shuttle Pharmaceuticals has insignificant predictability. Overlapping area represents the amount of predictability between Shuttle Pharmaceuticals time series from 17th of November 2025 to 1st of January 2026 and 1st of January 2026 to 15th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Shuttle Pharmaceuticals price movement. The serial correlation of 0.12 indicates that less than 12.0% of current Shuttle Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.12 | |
| Spearman Rank Test | -0.23 | |
| Residual Average | 0.0 | |
| Price Variance | 0.14 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Shuttle Pharmaceuticals reported net income of (9.14 Million). This is 102.68% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 101.6% higher than that of the company.
Shuttle Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shuttle Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shuttle Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Shuttle Pharmaceuticals by comparing valuation metrics of similar companies.Shuttle Pharmaceuticals is currently under evaluation in net income category among its peers.
Shuttle Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Shuttle Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Shuttle Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Shuttle Pharmaceuticals' value.| Shares | Ubs Group Ag | 2025-06-30 | 3.4 K | Tower Research Capital Llc | 2025-06-30 | 123 | Barclays Plc | 2025-03-31 | 3.0 | Bank Of America Corp | 2025-06-30 | 3.0 | Federation Des Caisses Desjardins Du Quebec | 2025-06-30 | 2.0 | Geode Capital Management, Llc | 2025-06-30 | 0.0 | Armistice Capital, Llc | 2025-06-30 | 0.0 | Two Sigma Securities, Llc | 2025-06-30 | 0.0 | Citadel Advisors Llc | 2025-06-30 | 0.0 |
Shuttle Fundamentals
| Return On Equity | -271.76 | ||||
| Return On Asset | -3.23 | ||||
| Current Valuation | 1.55 M | ||||
| Shares Outstanding | 2.68 M | ||||
| Shares Owned By Insiders | 1.90 % | ||||
| Shares Owned By Institutions | 6.86 % | ||||
| Number Of Shares Shorted | 619.06 K | ||||
| Price To Book | 2.14 X | ||||
| EBITDA | (7.78 M) | ||||
| Net Income | (9.14 M) | ||||
| Cash And Equivalents | 50.44 K | ||||
| Total Debt | 1.17 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 0.03 X | ||||
| Book Value Per Share | 1.13 X | ||||
| Cash Flow From Operations | (7.33 M) | ||||
| Short Ratio | 0.09 X | ||||
| Earnings Per Share | (3.42) X | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 2.98 M | ||||
| Total Asset | 2.51 M | ||||
| Retained Earnings | (34.58 M) | ||||
| Working Capital | 677.15 K | ||||
| Net Asset | 2.51 M |
About Shuttle Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shuttle Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shuttle Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shuttle Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Shuttle Stock please use our How to Invest in Shuttle Pharmaceuticals guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is there potential for Biotechnology market expansion? Will Shuttle introduce new products? Factors like these will boost the valuation of Shuttle Pharmaceuticals. If investors know Shuttle will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Shuttle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Shuttle Pharmaceuticals is measured differently than its book value, which is the value of Shuttle that is recorded on the company's balance sheet. Investors also form their own opinion of Shuttle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Shuttle Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Shuttle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Shuttle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Shuttle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shuttle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Shuttle Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.